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 Abstract 
 
Mutational processes occur in normal tissues from conception throughout life. Field cancerization 
describes the preconditioning of an area of epithelium to tumor growth. Pre-invasive lesions may arise 
in these fields, however only a minority of pre-invasive neoplasia progresses to overt malignancy. 
Within this review we discuss recent advances in our understanding of genomic instability processes 
in normal tissue, describe evolutionary dynamics in pre-invasive disease and highlight current 
evidence describing how increasing genomic instability may drive the transition from pre-invasive to 
invasive disease. Appreciation of the evolutionary rulebooks that operate in pre-invasive neoplasia 
may facilitate screening strategies, risk-stratification of pre-invasive lesions and precipitate novel 
preventative treatments in at-risk patient populations. 
 
Highlights 
 
 Discussion of evidence regarding clonal evolution in normal tissue. 
 An overview of field cancerization. 
 Evolutionary dynamics operating in the pre-invasive to invasive transition. 
 Clinical applications of this knowledge. 
 
Introduction 
 
Multicellular organisms repress individual cellular fitness to maintain ordered tissue 
homeostasis and consequently the fitness of the organism. The cancer phenotype represents the 
degradation of processes associated with this multicellular collectivism, whereby an individual 
cell achieves its own fitness at the expense of its host [1]. It was Peter Nowell in 1976 who first 
postulated a comprehensive framework describing that this process could be driven by 
evolutionary rules [2]. With the advent of large-scale sequencing technologies, this hypothesis 
has been confirmed [3-6]. In this review we summarise current evidence for genomic instability 
processes operating in normal tissues and discuss the dynamics underlying the pre-invasive 
stage of neoplasia that fuel the transition to invasive malignancy. 
 
Genomic instability and clonal evolution in histologically normal tissues 
 Genomic instability refers to the higher rate  of genetic aberrations observed in cancer and comprises 
the whole spectrum of genetic aberrations from point mutations through to chromosomal level 
aberrations. A recent deep-sequencing study of normal sun-exposed eyelid epidermis investigated 
whether genomic instability is detectable in normal tissue [7]. Through deep-sequencing of 74 cancer 
genes in 234 biopsies isolated from the eyelids of four different individuals, 3760 somatic mutations 
were identified, largely occurring in the ultraviolet mutational signature context. Evidence for ~140 
driver gene mutations in a cm2 of epidermis was observed, with clonal expansions occupying up to 
several mm2 of skin area suggesting the presence of hundreds of evolving clonal populations [7]. 
Strong positive selection was observed within the skin samples, evidenced by an increased ratio of 
nonsynomous (protein-altering) mutations versus synonymous (background) mutations in six genes, 
including NOTCH1 and TP53.  The sizes of clones containing mutations in these positively selected 
driver genes were compared to sizes of clones harboring synonymous mutations in non-driver genes 
(which would be selectively neutral). Clones containing driver mutations were significantly larger than 
clones containing neutral mutations for three of the six positively selected driver genes, however this 
difference in size was unexpectedly small. Martincorena et al. suggested that the observed limited 
clonal proliferation associated with driver gene events could represent a protection mechanism to 
guard against cancer development, potentially mediated by density dependent-growth constraints [7]. 
Simons re-analysed Martincorena et al.’s data and demonstrated that neutral growth dynamics were 
largely maintained in epidermal clones regardless of driver mutation status. It was noted that the 
observation of predominant neutral clonal growth created a paradox when coupled with evidence of 
positive selection of non-synonymous driver mutations [8]. In reply, Martincorena et al. discussed that 
the observations of neutral clonal growth dynamics and positive selection are not incompatible and 
could reflect initial clonal expansions falling beyond the detection limit of deep-sequencing. They 
suggested that initial exponential growth of a clonal population, due to acquisition of a driver mutation, 
could be followed by reversion to neutral drift due to physical growth constraint. [9]. This issue is yet 
to be fully resolved and it is likely that further studies will be necessary to ascertain if driver mutations 
do indeed produce a survival advantage in normal tissues [10]. 
 
Mutational processes either from exogenous or endogenous origin, can potentially contribute to the 
development of pre-cancerous clones. These mutational processes are believed to have specific 
underlying mechanisms and can be characterized by their trinucleotide context, also known as 
mutational signatures [11]. Currently more than 30 different signatures have been identified [12]. 
There is strong evidence that several mutational processes are active from conception throughout life 
in normal tissue [13,14].   Observations of multifocal patches of clonal populations with cancer-related 
genetic aberrations are not restricted to the skin [7], but have amongst others also been found in lung 
epithelium [15-18], breast epithelium [19,20] and intestinal epithelium in patients with ileocolitis [21] 
(Figure 1). Collectively, literature points towards mixed mutational processes active in normal tissues 
from conception, varying in strength over space and time.  
  
Field cancerization predisposes normal tissue to the formation of neoplasia  
 
The above studies provide evidence of a patchwork of clonal competition in epithelium and support 
Slaughter et al.’s hypothesis of field cancerization (or field defect) (Figure 1).  They defined field 
cancerization as a patch of epithelium that has been preconditioned by carcinogen exposure, 
facilitating the process towards cancer formation and enabling the formation of multifocal malignant 
disease [22]. More recent studies have also implicated epigenetic dysregulation of cancer cells in the 
process of field cancerization in the colon [23,24] and esophagus [25,26]. Epigenetic changes induced 
in dermal fibroblasts by exposure to ultraviolet light may also contribute to field cancerization, through 
dysregulating local release of factors including cytokines and matrix-remodelling enzymes [27]. 
Collectively, these data led to the refined definition of field cancerization by Graham et al. as “the 
preconditioning of an area of epithelium to tumor growth, either as the result of a clonal proliferation 
of mutant cells through the epithelium without causing neoplasia or because of consistent changes to 
cells in the stromal compartment” [28].  
 
In general, we can distinguish three types of fields, a normal field, carcinogen-exposed field and 
genetically-predisposed field. A normal field is the starting point in which a tissue has not yet acquired 
the molecular aberrations that predisposes to cancer development. In contrast, a carcinogen-
exposed field has acquired (epi)genetic oncogenic aberrations either through exogenous factors 
(such as UV-exposure [29] and smoking [18]) or endogenous processes (such as age-related 
spontaneous deamination [13] or APOBEC-mutagenesis [30] and can underlie the emergence 
of a sporadic cancer. A patient with a cancer predisposing germline mutation, harbors a 
genetically predisposed field of epithelium. The germline mutation determines which type of 
epithelium is affected and is predisposed to field cancerization. For example, patients with 
familial adenomatous polyposis (FAP) have germline APC mutations, which causes a field 
defect in the colon even though the mutation is present in every cell.  These patients will 
eventually develop hundreds to thousands of polyps which can eventually progress to a 
malignant outgrowth.  
 Evolutionary dynamics in pre-invasive lesions 
 
Pre-invasive lesions such as colonic adenoma and Barrett’s Esophagus (BE) are characterised 
by abnormal histological features and may demonstrate cytological atypia consistent with 
dysplasia [31,32]. The majority of pre-invasive lesions do not progress to malignancy. The risk 
of transformation from colonic adenoma to carcinoma is estimated at only 0.25% a year [33] 
and less than five percent of patients with BE progress to esophageal adenocarcinoma (EAC) 
in their lifetimes [34,35]. In pre-invasive lesions that do progress to invasive neoplasia, the pre-
invasive stage can last years to decades [36].  Within this section we use understanding gained 
through study of precursor lesions to gain insight into the evolutionary rules and dynamics that 
underlie the pre-invasive stage of carcinogenesis and drive the transition to invasive 
malignancy. 
 
Barrett’s Esophagus 
 
BE represents a precursor to EAC and is characterised by the replacement of normal squamous 
epithelium with glandular columnar epithelium within the lower portion of the esophagus [37]. 
Early work identified clonal heterogeneity within BE and suggested that clonal dynamics 
operating within BE may be subject to evolutionary rules [38]. BE epithelium is diverse, 
harboring multiple clonal populations and is highly mutated, demonstrating a somatic mutation 
rate higher than that of several other invasive carcinomas [39,40]. Martinez et al. conducted 
multi-color FISH on single-cells isolated from endoscopic brushings of non-dysplastic BE 
segments to map evolutionary dynamics occurring within BE over time. They observed that 
non-dysplastic BE is largely in a state of dynamic equilibrium with rare clonal contractions 
offset by clonal expansions leading to relative evolutionary stasis. Interestingly, clones 
containing CDKN2A-loss were observed to contract with time in this investigation. Since reflux 
control through acid suppression therapy was an inclusion criterion for this study, the authors 
hypothesised that CDKN2A-loss clones carry a survival advantage in an acid reflux 
environment and that following removal of this exogenous selection pressure genetic 
normalisation ensued [41]. Ross-Innes et al. performed targeted sequencing on 73 BE tissue 
samples taken from a single patient on multiple occasions over a three-year period. Six distinct 
clonal groups of neoplastic cells were identified and all six clones remained present within the 
Barrett’s Segment throughout follow-up. The only alteration in the clonal composition of the 
BE segment occurred following endoscopic treatment which resulted in the shrinkage of a 
single clone [40]. This again suggests that neoplastic clones largely exist in a state of 
equilibrium within BE and highlights the absence of clonal sweeps or fixation events within a 
three-year follow-up period.  
 
BE is present in nearly all patients with EAC [42] and studies profiling matched BE epithelium 
with EAC from the same esophagectomy specimen show shared somatic mutations in the 
majority of cases, however the degree of molecular genetic overlap varies substantially 
[40,43,44]. Given that evidence for BE and EAC sharing a common ancestor exists, the 
question arises why do some Barrett’s clones progress to cause invasive cancer, whereas others 
remain as in situ precursor lesions? In BE it has been demonstrated that ecological measures 
of clonal diversity strongly predict progression to invasive EAC [45]. Expanding on this 
concept further studies suggest that genomic instability generates this diversity. For example, 
patients who do not progress to EAC have relatively stable somatic chromosomal aberrations 
including localised CDKN2A deletions, 9p loss and copy number neutral loss of heterozygosity. 
In contrast patients who do progress to EAC develop chromosome instability, genomic 
diversity and selection of somatic copy number alterations including amplifications and 
genome doublings events [46,47].   
 
Insight into the genomic events associated with the acquisition of genomic instability and 
progression to EAC was provided by Stachler et al., who compared BE and EAC specimens 
identified in the same esophagectomy specimens. In eleven BE cases clonally unrelated to their 
paired EAC, representing BE populations that did not progress to EAC, only a single TP53 
alteration was observed. Four unrelated BE segments contained homozygous CDKN2A 
deletions, whereas the EACs that developed in these patients lacked these alterations. In 
contrast, analysis of fourteen BE cases clonally related to their paired EAC, revealed that TP53 
mutations were shared between BE and EAC segments in seven cases. In these cases, shared 
CDKN2A somatic alterations were not observed [43]. Given these findings, perhaps BE clones 
with early CDKN2A deletion are able to tolerate mutagenesis induced by an acidic environment 
through avoiding apoptosis. These clonal populations continue to proliferate but do not 
progress toward genomic instability, occupying a relative “evolutionary cul-de-sac” (Figure 1). 
On the other hand, clones that acquire early TP53 mutations, permissive for tolerance of DNA 
damage and ongoing genomic instability, undergo genome doubling and diversification 
acquiring further tumor suppressor gene inactivation and oncogene amplification events. This 
increases the evolutionary tempo operating within a BE segment, consequently leading to 
propensity for invasion [43,46].  In support of this theory, TP53 is recurrently mutated in 
dysplastic-BE [48], which is associated with occult EAC in up to 40% of cases [49], yet rarely 
mutated in non-dysplastic BE segments [48], which only progress to EAC in approximately 1 
in 300 patients [50]. Furthermore, there is evidence to suggest TP53 mutations facilitate the 
transition toward genomic instability in EAC carcinogenesis. TP53 mutations were found to be 
pre-genome doubling events in 90% of 144 EACs analysed by whole exome sequencing [43] 
suggesting that they are acquired prior to the onset of chromosomal instability. We observed 
early ubiquitous TP53 disruption in eight multi-region sequenced EAC cases, all cases 
demonstrated evidence of genome doubling and in two cases chromothripsis was observed 
[51]. These findings suggest that TP53 loss might permit complex genomic rearrangements in 
BE, facilitating macro-evolutionary leaps toward EAC; fuelling a cancer dominated by large 
scale rearrangement events including chromothripsis and kataegsis [52]. 
 
Colonic adenoma 
 
Colonic adenomas are thought to represent a precursor lesion to colonic adenocarcinoma on 
the basis of clinical and pathological evidence [53]. Adenomas are comprised of multiple 
genomically distinct populations of neoplastic cells [54,55]. DNA methylation analysis has 
revealed that crypts from a colonic adenoma are largely epigenetically diverse, regardless of 
spatial separation [56,57]. This suggests relative evolutionary stasis of clonal populations 
within adenoma crypts; since in a tumor comprising of clones undergoing continual expansions 
and contractions, spatially separated homogenous methylation patterns would be expected [58]. 
However, rare clonal expansions occurring within adenomas have been observed, suggesting 
that colonic adenoma, in a similar fashion to BE, may conform to a “punctuated” model of 
clonal evolution whereby expansion occurs rarely and stasis is the norm [56].  
 
When adenomas are identified clinically they are removed, hence longitudinal monitoring of 
the adenoma to carcinoma transition is not feasible in the same fashion as that achieved in BE. 
However, evidence points toward the involvement of chromosomal instability processes. 
Colorectal carcinomas have been demonstrated to be more chromosomally instable than 
adenomas by whole genome single nucleotide polymorphism arrays [59] and separate analyses 
of genomic imbalances in the adenoma and carcinoma components present in “malignant 
polyps” (small adenocarcinomas arising in high grade adenomas) revealed considerably more 
chromosomal losses and gains within the carcinoma region as compared with the adenoma 
region suggesting increased chromosomal instability during tumor progression [60]. 
Interestingly gain of 20q has been associated with the adenoma to carcinoma transition in 
malignant polyps [60,61] and adenomas from patients with FAP with allelic imbalance in 20q 
have a significantly higher mutational rate than non 20q altered adenomas [55]. We noted 18q 
as the most frequently lost chromosomal region in aneuploid colorectal tumors [62]. Through 
analysis of colorectal adenomas and carcinomas in the same surgical specimens, we implicated 
this event in the adenoma to carcinoma transition. Three chromosomal instability suppressor 
genes, PIGN, RKHD2 and ZNF516, were identified on 18q. Silencing of these genes induced 
structural and numeric genomic instability through replication stress and chromosome 
missegregation events [62]. These findings suggest that punctuated events inducing genomic 
instability may increase the evolutionary tempo operating in pre-invasive disease, facilitating 
progression toward invasive carcinoma. 
  
 
Cell-fate dynamics, transcriptional re-programming and the transition to invasive 
carcinoma 
 
Further insight into the events that associate with the pre-invasive to invasive transition can be 
provided by animal models. Oncogenic events acquired during carcinogenesis can influence 
cell-fate dynamics pre-disposing to an invasive phenotype. High-grade esophageal dysplasia 
(HGD) represents the precursor lesion to esophageal squamous cell carcinoma (ESC). Frede et 
al. investigated a murine model of ESC development based on sorafenib- and 
diethylnitrosamine-initiated carcinogenesis. Genetic lineage tracing was performed, which 
demonstrated that HGD can arise from multiple cells, suggesting a polyclonal origin of this 
lesion. The transition of in situ HGD to invasive ESC could be initiated by induction of 
KRASG12D expression in esophageal epithelium. In HGD, a single proliferating population was 
observed, with a small propensity for producing daughter cells that continued to divide, 
whereas in KRASG12D induced ESC, a larger imbalance in cell-fate was observed in a subset of 
clones strongly biased towards production of dividing over non-dividing progeny. This study 
suggests that oncogenic events alter cell-fate dynamics influencing tumor growth and that this 
associates with invasive behaviour [63]. Tumor suppressor gene inactivation can also bias cell-
fate toward proliferation, as TP53 mutant cells in the epidermis can produce an excess of 
proliferative over differentiated progeny in UV-exposed skin [64].  
 Deregulation of transcriptional networks has also been observed to associate with the 
development of invasive potential in animal-models. Transgenic expression in Zebrafish 
melanocytes of BRAFV600E, with concomitant deletion of TP53, leads to melanoma 
development, however only a small number of melanocytes develop into melanomas in this 
model [65]. Through use of an in vivo reporter of neural crest-progenitor (NCP) state it was 
demonstrated that clusters of melanocytes within a BRAFV600E mutant, TP53 deficient "cancer 
field”, regress to a NCP identity and it is these cells that display tumorigenic properties and 
progress to form invasive melanoma. SOX10, a transcription factor involved in melanocyte 
development, was identified as contributing to this reprogramming of melanocytes toward an 
embryonic NCP state [66]. Further studies support the concept that transcriptional 
reprogramming may underlie the generation of invasive potential (Figure 1). Interfollicular 
epidermis stem cells undergo reprogramming to a transcriptional state resembling embryonic 
hair follicle progenitors before progressing into invasive basal cell carcinoma, Wnt-/β-catenin 
signalling drives this cellular reprogramming in a SOX9 dependent manner [67,68]. Boumahdi 
et al. identified SOX2 as the most upregulated transcription factor in cancer stem cells derived 
from murine squamous cell carcinomas of the skin. In this study it was demonstrated that SOX2 
has an essential role in squamous cell carcinoma initiation and that tumor epithelial cells 
expressing this transcription factor reactivated a gene network reminiscent of the embryonic 
epidermis [69].  
 
Applying understanding of pre-invasive neoplasia to impact clinical care 
 
Considerable effort is being directed towards the advancement of screening and diagnostic 
strategies to diagnose neoplasia at an early point in its development, when clinical intervention 
could be curative. For example, it is now feasible to identify cell-free DNA released from pre-
invasive and minimally invasive lung neoplasia in plasma [70]; an approach that could be built 
upon for the early-detection of patients at risk of developing lung malignancy. As strategies 
such as these mature across tumor-types, the number of pre-invasive lesions diagnosed will 
increase. Only a minority of pre-invasive neoplasia transitions to invasive disease [33,35] and 
a proportion of pre-invasive neoplasia spontaneously regresses without treatment, e.g. in cases 
of cervical intraepithelial neoplasia [71] and pre-invasive bronchial lesions [72]. The challenge 
for the clinician will involve monitoring and risk-stratifying of identified pre-invasive lesions, 
to prevent morbidity associated with overtreatment. A thorough understanding of the 
evolutionary rules and genetic events governing the pre-invasive to invasive transition 
promises to inform these strategies by delineating low-risk and high-risk pre-invasive entities. 
There is already evidence to suggest that molecularly informed approaches to monitoring pre-
invasive disease can show clinical utility. The Cytosponge is a non-endoscopic device designed 
to acquire BE samples, analysis of Cytosponge samples using a multi-biomarker panel 
including TP53 mutation status can identify patients at low-risk of progression to EAC [73]. In 
these patients invasive endoscopy could potentially be avoided. Additionally, an understanding 
of pre-invasive malignancy and the tissue microenvironment associated with malignant 
progression has the potential to precipitate novel, preventive treatment strategies. These include 
vaccination strategies and therapeutic modulation of inflammatory pathways within the tissue 
microenvironment that promote tumorigenesis [74]. Integration of data from experimental 
models of pre-invasive progression, large-scale sequencing initiatives and non-invasive 
monitoring of at-risk patients will be required to facilitate personalized approaches for early 
cancer treatment and prevention. To this end, there are already calls for a “big-data” efforts to 
improve understanding of pre-invasive disease [75]. 
 
Conclusion 
 
Genomic instability processes occur throughout life from conception, this generates diversity 
and acts as a substrate for selection. Within this review we discuss early mutational processes 
occurring within normal-appearing tissue that lead to gain of oncogenic events and loss of 
tumor suppressor gene activity, a process known as field cancerization or field defect. This 
predisposes tissue fields to the development of pre-invasive histological atypia such as BE. 
Studies of BE reveal an epithelium consisting of multiple clones that are largely evolutionary 
static. Some clones may be born to be bad and develop genomic instability resulting in rapid 
acquisition of oncogene events and tumor suppressor gene loss, facilitating the transition to 
invasive malignancy. Studies in animal models demonstrate that transcriptional 
reprogramming and oncogene-induced disruption of cell-fate may also contribute to the 
transition from pre-invasive to invasive disease. We now enter an exciting stage in cancer 
medicine, where large-scale genomic analyses are providing a previously unachievable 
resolution by which the evolutionary dynamics underlying carcinogenesis can be appreciated 
in detail. Although work still needs to be done to understand the contribution of the stromal 
compartment to the development of invasive neoplasia, we may reach a point at which the 
evolutionary rules that dictate the development of cancer can be appreciated. This 
understanding would lead to more meaningful, rational monitoring of pre-invasive neoplasia 
and targeted intervention to intercept cancer formation at the earliest stage, significantly 
reducing cancer-related morbidity. 
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Tables and captions 
 
Figure 1. Evolutionary dynamics of ongoing mutational processes contributing to the 
development of neoplasia. From conception, mutational processes contribute to the 
acquisition of passenger and driver mutations. This leads to the expansion of clonal populations 
within histologically normal-appearing tissue. Nevertheless, due to tumor-suppressive factors, 
most clonal populations are unable to progress toward genomic instability, occupying a relative 
“evolutionary cul-de-sac”. Through transcriptional reprogramming and loss of tumour 
suppressor genes, some clones do progress and acquire the capability to tolerate extensive 
levels of genomic instability. This increases the evolutionary tempo which eventually enables 
the acquisition of an invasive and metastatic phenotype. Please note that the timescale is not 
proportional. 
 
